"id","uuid:ID","versionIdentifier","instanceType","rationale"
"StudyVersion_1","28fce7a8-5e6d-45aa-8380-1540c45496a3","2","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
